Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma

Pazdur, Richard, Wagman, Lawrence, Camphausen, Kevin, Hoskins, William, Cancer Management: a Multidisciplinary Approach, 11th Edition, 2008. Azoury, 2014, Epidemiology, risk factors, prevention, and early detection of Melanoma, Surg Clin North Am, 94, 945, 10.1016/j.suc.2014.07.013 Wróbel, 2019, The clinical trial landscape for Melanoma therapies, J Clin Med., 8, 368, 10.3390/jcm8030368 Mardani, 2020, Nanomicellar-curcumin exerts its therapeutic effects via affecting angiogenesis, apoptosis, and T cells in a mouse model of Melanoma Lung Metastasis, Pathol Res Pract, 216, 10.1016/j.prp.2020.153082 Bagheri, 2020, CXCL-10: a new candidate for melanoma therapy?, Cell Oncol (Dordr), 43, 353, 10.1007/s13402-020-00501-z Pourhanifeh M.H., Abbaszadeh-Goudarzi K., Goodarzi M., et al. Resveratrol: a new potential therapeutic agent for melanoma? [published online ahead of print, 2019 Dec 11]. Curr Med Chem. 2019; 10.2174/0929867326666191212101225. doi:10.2174/0929867326666191212101225. Mirzaei, 2018, The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model, Cancer Lett, 419, 30, 10.1016/j.canlet.2018.01.029 Hallajzadeh, 2020, Circular RNAs: new genetic tools in Melanoma, Biomark Med, 14, 563, 10.2217/bmm-2019-0567 Bhatia, 2009, Treatment of Metastatic Melanoma: an Overview, Oncology (Williston Park), 23, 488 Schwartz, 2016, RECIST 1.1-Update and clarification: from the RECIST committee, Eur J Cancer, 62, 132, 10.1016/j.ejca.2016.03.081 Nishino, 2010, New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy, AJR Am J Roentgenol, 195, W221, 10.2214/AJR.09.3928 1979, 48 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082 Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 16, 375, 10.1016/S1470-2045(15)70076-8 Larkin, 2014, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, N Engl J Med, 371, 1867, 10.1056/NEJMoa1408868 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma [published correction appears in N Engl J Med. 2010 Sep 23;363(13):1290], N Engl J Med., 363, 711, 10.1056/NEJMoa1003466 Voskoboynik, 2014, Combination therapies for the treatment of advanced melanoma: a review of current evidence, Biochem Res Int, 2014, 10.1155/2014/307059 Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X Ribas, 2015, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, 16, 908, 10.1016/S1470-2045(15)00083-2 Robert, 2015, Pembrolizumab versus Ipilimumab in Advanced Melanoma, N Engl J Med, 371, 2521, 10.1056/NEJMoa1503093 Algazi, 2015, SWOG S1320: a randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma, J Clin Oncol, 33, 15, 10.1200/jco.2015.33.15_suppl.tps9093